AERIUS DOUBLE ACTION 12 HOUR TABLET (EXTENDED-RELEASE)

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

Pieejams no:

BAYER INC

ATĶ kods:

R01BA52

SNN (starptautisko nepatentēto nosaukumu):

PSEUDOEPHEDRINE, COMBINATIONS

Deva:

2.5MG; 120MG

Zāļu forma:

TABLET (EXTENDED-RELEASE)

Kompozīcija:

DESLORATADINE 2.5MG; PSEUDOEPHEDRINE SULFATE 120MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

2/4/7/10/14/20/30

Receptes veids:

OTC

Ārstniecības joma:

SECOND GENERATION ANTIHISTAMINES

Produktu pārskats:

Active ingredient group (AIG) number: 0252460001; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2014-12-05

Produkta apraksts

_< AERIUS® SINUS + ALLERGY > _
_ _
_< Desloratadine 2.5 mg & Pseudoephedrine sulfate 120 mg> _
_Page 1 of 36_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
AERIUS® SINUS + ALLERGY
Desloratadine and Pseudoephedrine sulfate Extended-Release Tablets
Extended-release tablets, Desloratadine 2.5 mg / Pseudoephedrine
Sulfate 120 mg, Oral
Histamine H1 Receptor Antagonist / Sympathomimetic Amine
Bayer Inc
Date of Authorization: February 1
st
, 2010
2920 Matheson Blvd. E
Date of Revision: February 20
th
, 2024
Mississauga, ON
L4W 5R6
Submission Control Number: 278741
® TM see www.bayer.ca/tm-mc
_ _
_< AERIUS® SINUS + ALLERGY > _
_ _
_<_
_Desloratadine 2.5 mg & Pseudoephedrine sulfate 120 mg> _
_Page 2 of 36_
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
PART I: HEALTH PROFESSIONAL INFORMATION .......................................................................
4
1 INDICATIONS ...........................................................................................................................
4
1.1 Pediatrics
...............................................................................................................................
4
1.2 Geriatrics
...............................................................................................................................
4
2 CONTRAINDICATIONS .............................................................................................................
4
3 SERIOUS WARNINGS AND PRECAUTIONS BOX ......................................................................
4
4 DOSAGE AND ADMINISTRATION ............................................................................................
5
4.1 Dosing Considerations
..........................................................................................................
5
4.2 Recommended Dose and Dosage Adjustment
.....................................................................
5
4.4 Administration
...............................